You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer
|
|---|---|
| Published in |
European Journal of Cancer (1965), April 2014
|
| DOI | 10.1016/j.ejca.2014.03.007 |
| Pubmed ID | |
| Authors |
Christian Dittrich, Zsolt Papai-Szekely, Nuria Vinolas, Christer Sederholm, Joerg T. Hartmann, Dirk Behringer, Gbenga Kazeem, Durisala Desaiah, Monika I. Leschinger, Joachim von Pawel |
| Abstract |
Pemetrexed and erlotinib have been approved as second-line monotherapy for locally advanced or metastatic non-small cell lung cancer (NSCLC). This multicentre, randomised, open-label, parallel phase II study assessed efficacy and safety of pemetrexed versus pemetrexed+erlotinib in patients with advanced non-squamous NSCLC. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Sao Tome and Principe | 1 | 25% |
| India | 1 | 25% |
| United Kingdom | 1 | 25% |
| Unknown | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
| Members of the public | 1 | 25% |
| Scientists | 1 | 25% |
| Science communicators (journalists, bloggers, editors) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 2% |
| Unknown | 60 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 10 | 16% |
| Other | 9 | 15% |
| Student > Bachelor | 8 | 13% |
| Student > Doctoral Student | 6 | 10% |
| Researcher | 5 | 8% |
| Other | 11 | 18% |
| Unknown | 12 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 33% |
| Nursing and Health Professions | 6 | 10% |
| Engineering | 4 | 7% |
| Economics, Econometrics and Finance | 2 | 3% |
| Psychology | 2 | 3% |
| Other | 12 | 20% |
| Unknown | 15 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 June 2023.
All research outputs
#4,192,244
of 25,374,917 outputs
Outputs from European Journal of Cancer (1965)
#1,284
of 6,871 outputs
Outputs of similar age
#39,340
of 238,770 outputs
Outputs of similar age from European Journal of Cancer (1965)
#8
of 79 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,871 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.1. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 238,770 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 79 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.